Journal articles: 'Primary brain tumor'

1

&NA;. "Responding to primary brain tumor." Nursing 37, no. 1 (January 2007): 43. http://dx.doi.org/10.1097/00152193-200701000-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tamura, Ryota, Yoshiaki Kuroshima, and Yoshiki Nakamura. "Primary Neuroendocrine Tumor in Brain." Case Reports in Neurological Medicine 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/295253.

Full text

Abstract:

The incidence of brain metastases for neuroendocrine tumor (NET) is reportedly 1.5~5%, and the origin is usually pulmonary. A 77-year-old man presented to our hospital with headache and disturbance of specific skilled motor activities. Computed tomography (CT) showed a massive neoplastic lesion originating in the left temporal and parietal lobes that caused a mass edematous effect. Grossly, total resection of the tumor was achieved. Histological examination revealed much nuclear atypia and mitotic figures. Staining for CD56, chromogranin A, and synaptophysin was positive, indicating NET. The MIB-1 index was 37%. Histopathologically, the tumor was diagnosed as NET. After surgery, gastroscopy and colonoscopy were performed, but the origin was not seen. After discharge, CT and FDG-PET (fluoro-2-deoxy-d-glucose positron emission tomography) were performed every 3 months. Two years later we have not determined the origin of the tumor. It is possible that the brain is the primary site of this NET. To our knowledge, this is the first reported case of this phenomenon.

APA, Harvard, Vancouver, ISO, and other styles

3

Gilbert, Mark R. "Primary brain tumors, delta 24 and tumor metabolism." Expert Review of Neurotherapeutics 13, no. 4 (April 2013): 353–55. http://dx.doi.org/10.1586/ern.13.28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Tunjungsari, Dyah, DjumhanaAtmakusuma, Freddy Sitorus, Joedo Prihartono, Teguh A. S. Ranakusuma, Salim Harris, Astri Budikayanti, and Tiara Aninditha. "Coagulation Profile Comparison Between Primary Brain Tumor and Secondary Brain Tumor." Advanced Science Letters 24, no. 9 (September 1, 2018): 6437–41. http://dx.doi.org/10.1166/asl.2018.12739.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Stone, Jacqueline B., Joanne F. Kelvin, and Lisa M. DeAngelis. "Fertility preservation in primary brain tumor patients." Neuro-Oncology Practice 4, no. 1 (December 9, 2016): 40–45. http://dx.doi.org/10.1093/nop/npw005.

Full text

Abstract:

Abstract Background Fertility preservation (FP) is an infrequently addressed issue for young adults with primary brain tumors. Given the improved prognosis and enhanced technology in reproductive medicine, more primary brain tumor patients see procreation as feasible, making the discussion of FP increasingly important. The goals of this study were to describe patients who received FP counseling by a fertility nurse specialist (FNS) and determine which sociodemographic and disease-related factors predict acceptance of referral to a reproductive specialist. Methods Institutional review board-approved retrospective review of primary brain tumor patients, ages 18 to 45, who were referred for FP counseling with a FNS from 2009 to 2013. Results Seventy patients were referred for FP counseling: 38 men, 32 women, with a median age of 32 years and median KPS of 90. Eighty-nine percent had gliomas; 58% grade III, 17% grade IV. Sixty-seven percent were referred for counseling at initial diagnosis. Of those referred, 73% accepted referral to a sperm bank (87% of men) or reproductive endocrinologist (56% of women). Patients were more likely to accept referral if they had no prior children (P = .048). There was no statistically significant difference in referral acceptance by age, race/ethnicity, marital status, religion, or tumor grade. After treatment, 3 men conceived naturally, 2 men conceived using banked sperm, and 2 women conceived naturally. Conclusions Despite the historically poor prognosis of patients with primary brain tumors, there is significant interest in FP among these patients, particularly if they have no prior children. Clinicians should develop strategies to incorporate FP counseling into practice.

APA, Harvard, Vancouver, ISO, and other styles

6

Balachandran, Akilandeswari A., Leon M. Larcher, Suxiang Chen, and Rakesh N. Veedu. "Therapeutically Significant MicroRNAs in Primary and Metastatic Brain Malignancies." Cancers 12, no. 9 (September 7, 2020): 2534. http://dx.doi.org/10.3390/cancers12092534.

Full text

Abstract:

Brain cancer is one among the rare cancers with high mortality rate that affects both children and adults. The most aggressive form of primary brain tumor is glioblastoma. Secondary brain tumors most commonly metastasize from primary cancers of lung, breast, or melanoma. The five-year survival of primary and secondary brain tumors is 34% and 2.4%, respectively. Owing to poor prognosis, tumor heterogeneity, increased tumor relapse, and resistance to therapies, brain cancers have high mortality and poor survival rates compared to other cancers. Early diagnosis, effective targeted treatments, and improved prognosis have the potential to increase the survival rate of patients with primary and secondary brain malignancies. MicroRNAs (miRNAs) are short noncoding RNAs of approximately 18–22 nucleotides that play a significant role in the regulation of multiple genes. With growing interest in the development of miRNA-based therapeutics, it is crucial to understand the differential role of these miRNAs in the given cancer scenario. This review focuses on the differential expression of ten miRNAs (miR-145, miR-31, miR-451, miR-19a, miR-143, miR-125b, miR-328, miR-210, miR-146a, and miR-126) in glioblastoma and brain metastasis. These miRNAs are highly dysregulated in both primary and metastatic brain tumors, which necessitates a better understanding of their role in these cancers. In the context of the tumor microenvironment and the expression of different genes, these miRNAs possess both oncogenic and/or tumor-suppressive roles within the same cancer.

APA, Harvard, Vancouver, ISO, and other styles

7

Aulia Hanum, Achmad Bayhaqi Nasir Aslam, Yuyun Yueniwati, Diah Prabawati Retnani, and Nanik Setjowati. "Measurement of the peritumoral edema and tumor volume ratio in differentiating malignant primary and metastatic brain tumor." GSC Biological and Pharmaceutical Sciences 13, no. 2 (November 30, 2020): 055–61. http://dx.doi.org/10.30574/gscbps.2020.13.2.0295.

Full text

Abstract:

Malignant primary and metastatic brain tumors are group of malignancies radiologically difficult to distinguish between one another. Meanwhile, the treatment regimens between the two entities are very different. The right regimen can maintain patient’s survival. MRI is the modality of choice for diagnosing brain tumors; although, malignant primary brain tumors and solitary metastases appear similar on conventional MRI. The difference in the pathophysiology of peritumoral edema in malignant primary and metastatic brain tumors has the potential for differentiation of the two entities. In malignant primary brain tumors, tumor cell infiltration occurs in the edema area, meaning that the peritumoral edema is narrower than that of the metastases. This study analyzed the ratio of peritumoral edema volume to tumor (EP/T volume ratio) in malignant primary and metastatic brain tumors by means of MRI examination with a cross-sectional design, using MRI data on FLAIR and T1WI sequences with contrast in malignant brain tumor of patients that have been pathologically proven. Then, volume contouring was performed on peritumoral edema (EP) and tumor (T), and comparation was done to obtain the EP/T volume ratio. The ratio of EP/T volume data in both groups was analyzed using the Mann–Whitney test with the SPSS 22 software. The results of statistical analysis revealed that the EP/T volume ratio of the malignant primary brain tumor group was smaller with a median value (max-min) of 1.1 (5.65-0.17) and in the metastatic group, 2.3 (64.03-0.09). There was a significant difference in the EP/T volume ratio between the two groups, which the brain metastatic tumor group have a double ratio of EP/T with a value of p=0.008 (p<0.05).

APA, Harvard, Vancouver, ISO, and other styles

8

Kijima, Noriyuki, Yoshikazu Nakajima, Daisuke Kanematsu, Tomoko Shofuda, Yuichiro Higuchi, Hiroshi Suemizu, Kanji Mori, et al. "TMOD-29. ESTABLISHMENT OF PATIENT-DERIVED XENOGRAFTS FROM RARE PRIMARY BRAIN TUMORS." Neuro-Oncology 22, Supplement_2 (November 2020): ii234. http://dx.doi.org/10.1093/neuonc/noaa215.979.

Full text

Abstract:

Abstract Patient derived xenografts are essential tools for translational research and preclinical development of novel therapeutic strategies of primary brain tumors. Recent advances in genomics of primary brain tumors revealed molecular classification of primary brain tumors, thus establishment of patient derived xenografts from each subtype of primary brain tumors is urgently needed. However, currently available patient derived xenografts are limited and are from specific subtype of primary brain tumors such as glioblastoma IDH wild type. In this study, we aim to establish patient derived xenografts from primary brain tumors with various molecular characteristics, especially rare primary brain tumors. We got primary brain tumor tissues from patients, dissociated those tissue into single cells, and orthotopically injected those cells into NOD/Shi-scid IL2Rγ KO mouse. We successfully established rare patient-derived xenografts from atypical teratoid rhabdoid tumor and CNS Ewing sarcoma family tumor with CIC alteration, which is recently described as new entity of primitive neuroectodermal tumors of the CNS. We also analyzed histopathological characteristics of these xenografts and found that each xenograft well recapitulated histopathological features of original patients’ resected tumors. These xenografts have advantages for translational research and preclinical development of novel therapeutic strategies for rare primary brain tumors. In addition, further efforts are needed to establish other types of rare primary brain tumors.

APA, Harvard, Vancouver, ISO, and other styles

9

LIANG, RUICHAO, and FANG FANG. "THE APPLICATION OF NANOMATERIALS IN DIAGNOSIS AND TREATMENT FOR MALIGNANT PRIMARY BRAIN TUMORS." Nano 09, no. 01 (January 2014): 1430001. http://dx.doi.org/10.1142/s1793292014300011.

Full text

Abstract:

Malignant primary brain tumors have a very high morbidity and mortality. Even though enormous advances have been made in primary brain tumor management, in the case of malignant primary brain tumors, current diagnostic strategies cannot identify exact infiltrating margins, surgery alone cannot achieve total mass resection, and adjuvant therapies cannot improve survivals. Therefore, there is an urgent need to explore novel strategies to diagnose and treat such infiltrating brain tumors. Nanomaterials, particularly zero-dimensional and one-dimensional platforms, can carry various compounds such as contrast agents, anticancer drugs and genes into brain tumor cells specifically. Thus, contrast agent-based nanomaterials can selectively present infiltrating tumor outlines, while anticancer agent-based nanomaterials can specifically kill malignant tumor cells. In addition, dual-targeting nanomaterials, multifunctional nanocarriers, theranostic nanovehicles as well as convection-enhanced delivery technology hold promise to increase drug accumulation in tumor tissues, which could largely improve anticancer efficacy. In this review, we will mainly focus on the application of nanomaterials in preoperative diagnosis, intraoperative diagnosis and adjuvant treatment for malignant primary brain tumors.

APA, Harvard, Vancouver, ISO, and other styles

10

Wiffen, Philip J. "MULTIDISCIPLINARY REHABILITATION AFTER PRIMARY BRAIN TUMOR TREATMENT." Journal of Pain & Palliative Care Pharmacotherapy 27, no. 2 (June 2013): 180. http://dx.doi.org/10.3109/15360288.2013.810898.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Konstantinidou, A. E., P. Korkolopoulou, and E. Patsouris. "Apoptotic markers for primary brain tumor prognosis." Journal of Neuro-Oncology 72, no. 2 (April 2005): 151–56. http://dx.doi.org/10.1007/s11060-004-3345-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Osborn, A. G. "Cerebral Alveolar Echinoccosis Mimicking Primary Brain Tumor." Yearbook of Diagnostic Radiology 2006 (January 2006): 367–71. http://dx.doi.org/10.1016/s0098-1672(08)70486-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Sathornsumetee, Sith, and Jeremy N. Rich. "New approaches to primary brain tumor treatment." Anti-Cancer Drugs 17, no. 9 (October 2006): 1003–16. http://dx.doi.org/10.1097/01.cad.0000231473.00030.1f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Ho, Peter S. P., Wei-Hwa Lee, Cheng-Yu Chen, Ting-Ywan Chou, Yeou-Chih Wang, Min-Jye Sun, and Wen-Yu Liou. "Primary Malignant Rhabdoid Tumor of the Brain." Journal of Computer Assisted Tomography 14, no. 3 (May 1990): 461–63. http://dx.doi.org/10.1097/00004728-199005000-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Rainov, Nikolai G., Jan Lübbe, Jane Renshaw, Kathy Pritchard-Jones, Annette Ridolfi Lüthy, and Adriano Aguzzi. "Association of Wilmsʼ Tumor with Primary Brain Tumor in Siblings." Journal of Neuropathology and Experimental Neurology 54, no. 2 (March 1995): 214–23. http://dx.doi.org/10.1097/00005072-199503000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Claudio, Pier Paolo, Jagan Valluri, Sarah E. Mathis, Anthony Alberico, Thomas Alberico, James Denvir, Gerrit A. Kimmey, et al. "Chemopredictive assay for patients with primary brain tumors." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 2089. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.2089.

Full text

Abstract:

2089 Background: Cancer stem-like cells (CSLCs) in primary brain tumors can resist certain chemotherapies, thereby causing relapse of the disease. Thus, development of a test that identifies the most effective chemotherapy management offers great promise for personalized anticancer treatments. Methods: We have developed an ex vivo ChemoID assay designed to predict the sensitivity and resistance of CSLCs and bulk of tumor cells of a given patient's solid tumor to a variety of chemotherapy agents by measuring the percentage of cell death. In a retrospective study of five patients with malignancies of the central nervous system, we assessed the correlation between the results of the ChemoID assay and clinical response. Two anaplastic WHO grade-III ependymomas, two IDH-1 negative WHO grade 4 glioblastomas, and one medulloblastoma were tested. Tumors were classified as responsive (50-100% cell kill), intermediately responsive (30-50% cell kill), and nonresponsive (0-30% cell kill) to chemotherapy. Treatment selection was blinded to assay results. MRI and CT scan determined response to therapy. Results: The ChemoID assay performed on the tumor bulk produced a correct prediction in 4 out of 5 cases (p = 0.4, Fisher's Exact Test; PPV = 75%, NPV = 100%) when compared to the drugs received. The same assay performed on the CSLCs produced a correct prediction in all 5 cases (p = 0.1, Fisher's Exact Test; PPV=NPV=100%). Conclusions: An assay such as ChemoID that measures cell death of CSLCs and bulk of tumor cells appears to be beneficial in selecting specific standard chemotherapy agents ex vivo for patients with malignancies of the central nervous system.

APA, Harvard, Vancouver, ISO, and other styles

17

Warren, Katherine E., Joseph A. Frank, Jeanette L. Black, Rene S. Hill, Josef H. Duyn, Alberta A. Aikin, Bobbi K. Lewis, Peter C. Adamson, and Frank M. Balis. "Proton Magnetic Resonance Spectroscopic Imaging in Children With Recurrent Primary Brain Tumors." Journal of Clinical Oncology 18, no. 5 (March 1, 2000): 1020. http://dx.doi.org/10.1200/jco.2000.18.5.1020.

Full text

Abstract:

PURPOSE: Proton magnetic resonance spectroscopic imaging (1H-MRSI) is a noninvasive technique for spatial characterization of biochemical markers in tissues. We measured the relative tumor concentrations of these biochemical markers in children with recurrent brain tumors and evaluated their potential prognostic significance. PATIENTS AND METHODS: 1H-MRSI was performed on 27 children with recurrent primary brain tumors referred to our institution for investigational drug trials. Diagnoses included high-grade glioma (n = 10), brainstem glioma (n = 7), medulloblastoma/peripheral neuroectodermal tumor (n = 6), ependymoma (n = 3), and pineal germinoma (n = 1). 1H-MRSI was performed on 1.5-T magnetic resonance imagers before treatment. The concentrations of choline (Cho) and N-acetyl-aspartate (NAA) in the tumor and normal brain were quantified using a multislice multivoxel method, and the maximum Cho:NAA ratio was determined for each patient’s tumor. RESULTS: The maximum Cho:NAA ratio ranged from 1.1 to 13.2 (median, 4.5); the Cho:NAA ratio in areas of normal-appearing brain tissue was less than 1.0. The maximum Cho:NAA ratio for each histologic subtype varied considerably; approximately equal numbers of patients within each tumor type had maximum Cho:NAA ratios above and below the median. Patients with a maximum Cho:NAA ratio greater than 4.5 had a median survival of 22 weeks, and all 13 patients died by 63 weeks. Patients with a Cho:NAA ratio less than or equal to 4.5 had a projected survival of more than 50% at 63 weeks. The difference was statistically significant (P = .0067, log-rank test). CONCLUSION: The maximum tumor Cho:NAA ratio seems to be predictive of outcome in children with recurrent primary brain tumors and should be evaluated as a prognostic indicator in newly diagnosed childhood brain tumors.

APA, Harvard, Vancouver, ISO, and other styles

18

Brehar, F. M., R. M. Gorgan, and Angela Neacsu. "Brain metastases of neuroendocrine tumor with unknown primary location - Case report." Romanian Neurosurgery 20, no. 2 (June 1, 2013): 159–65. http://dx.doi.org/10.2478/romneu-2013-0005.

Full text

Abstract:

Abstract Neuroendocrine tumors are tumors derived from the cells of the neuroendocrine system. The majority of metastases of neuroendocrine tumors occur in liver, lungs and bone. The brain is an uncommon site of metastasize for this type of tumor. The authors of this paper present a case of brain metastases of neuroendocrine tumor with undetermined primary location. The patient, a 35 yearsold man, was admitted in our clinic with headache, nausea, vomiting and a mild right facial paresis. Head CT scan and cerebral MRI identified two lesions: one larger lesion with mixed solid and cystic components located in the left basal ganglia and thalamus and a second cystic lesion located deep in the right parietal lobe. All complementary investigations (including thoracic CT scan and whole-body MRI) failed to reveal the primary tumor location. Due to the high vital-risks associated with the open surgical procedure, the patient and his family chose the less invasive procedure of stereotactic biopsy. Postoperatively the patient had no additional neurologic deficits, presenting only the initial mild right central facial paresis. The result of immunohistochemistry examination was cerebral metastases of neuroendocrine tumor. The patient was directed to the Institute of Oncology Fundeni for further investigations and therapeutically management. In conclusion, even if these are rare tumors which rarely metastasize in the brain, the neurosurgeons should take in consideration this pathology when they examine a patient with multiple cerebral lesions with unknown location of primary tumor.

APA, Harvard, Vancouver, ISO, and other styles

19

Thomson, S. A. M., E. Kennerly, N. Olby, J. R. Mickelson, D. E. Hoffmann, P. J. Dickinson, G. Gibson, and M. Breen. "Microarray Analysis of Differentially Expressed Genes of Primary Tumors in the Canine Central Nervous System." Veterinary Pathology 42, no. 5 (September 2005): 550–58. http://dx.doi.org/10.1354/vp.42-5-550.

Full text

Abstract:

The pathophysiologic similarities of many human and canine cancers support the role of the domestic dog as a model for brain tumor research. Here we report the construction of a custom canine brain-specific cDNA microarray and the analysis of gene expression patterns of several different types of canine brain tumor The microarray contained 4000 clones from a canine brain specific cDNA library including 2161 clones that matched known genes or expressed sequence tags (ESTs) and 25 cancer-related genes. Our study included 16 brain tumors (seven meningiomas, five glial tumors, two ependymomas, and two choroid plexus papillomas) from a variety of different dog breeds. We identified several genes previously found to be differentially expressed in human brain tumors. This suggests that human and canine brain tumors share a common pathogenesis. In addition, we also found differentially expressed genes unique to either meningiomas or the glial tumors. This report represents the first global gene expression analysis of different types of canine brain tumors by cDNA microarrays and might aid in the identification of potential candidate genes involved in tumor formation and progression.

APA, Harvard, Vancouver, ISO, and other styles

20

Muldoon, Leslie L., Carole Soussain, Kristoph Jahnke, Conrad Johanson, Tali Siegal, Quentin R. Smith, Walter A. Hall, et al. "Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check." Journal of Clinical Oncology 25, no. 16 (June 1, 2007): 2295–305. http://dx.doi.org/10.1200/jco.2006.09.9861.

Full text

Abstract:

PurposeThis review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006.ResultsChemotherapeutic regimens in brain tumor therapy have often emerged from empirical clinical studies with retrospective pharmacologic explanations, rather than prospective trials of rational chemotherapeutic approaches. Brain tumors are largely composed of CNS metastases of systemic cancers. Primary brain tumors, such as glioblastoma multiforme or primary CNS lymphomas, are less common. Few of these tumors have well-defined optimal treatment. Brain tumors are protected from systemic chemotherapy by the blood-brain barrier (BBB) and by intrinsic properties of the tumors. Pharmacologic studies of delivery of conventional chemotherapeutics and novel therapeutics showing actual tumor concentrations and biologic effect are lacking.ConclusionIn this article, we review drug delivery across the BBB, as well as blood-tumor and –cerebrospinal fluid (CSF) barriers, and mechanisms to increase drug delivery to CNS and CSF tumors. Because of the difficulty in treating CNS tumors, innovative treatments and alternative delivery techniques involving brain/cord capillaries, choroid plexus, and CSF are needed.

APA, Harvard, Vancouver, ISO, and other styles

21

Pan, Wenying, Wei Gu, Seema Nagpal, Melanie Hayden Gephart, and Stephen R. Quake. "Brain Tumor Mutations Detected in Cerebral Spinal Fluid." Clinical Chemistry 61, no. 3 (March 1, 2015): 514–22. http://dx.doi.org/10.1373/clinchem.2014.235457.

Full text

Abstract:

Abstract BACKGROUND Detecting tumor-derived cell-free DNA (cfDNA) in the blood of brain tumor patients is challenging, presumably owing to the blood–brain barrier. Cerebral spinal fluid (CSF) may serve as an alternative “liquid biopsy” of brain tumors by enabling measurement of circulating DNA within CSF to characterize tumor-specific mutations. Many aspects about the characteristics and detectability of tumor mutations in CSF remain undetermined. METHODS We used digital PCR and targeted amplicon sequencing to quantify tumor mutations in the cfDNA of CSF and plasma collected from 7 patients with solid brain tumors. Also, we applied cancer panel sequencing to globally characterize the somatic mutation profile from the CSF of 1 patient with suspected leptomeningeal disease. RESULTS We detected tumor mutations in CSF samples from 6 of 7 patients with solid brain tumors. The concentration of the tumor mutant alleles varied widely between patients, from <5 to nearly 3000 copies/mL CSF. We identified 7 somatic mutations from the CSF of a patient with leptomeningeal disease by use of cancer panel sequencing, and the result was concordant with genetic testing on the primary tumor biopsy. CONCLUSIONS Tumor mutations were detectable in cfDNA from the CSF of patients with different primary and metastatic brain tumors. We designed 2 strategies to characterize tumor mutations in CSF for potential clinical diagnosis: the targeted detection of known driver mutations to monitor brain metastasis and the global characterization of genomic aberrations to direct personalized cancer care.

APA, Harvard, Vancouver, ISO, and other styles

22

Hohwieler, Marcia L., Theodore C. M. Lo, Mark L. Silverman, and Stephen R. Freidberg. "Brain Necrosis after Radiotherapy for Primary Intracerebral Tumor." Neurosurgery 18, no. 1 (January 1, 1986): 67–74. http://dx.doi.org/10.1227/00006123-198601000-00011.

Full text

Abstract:

Abstract Radiotherapy is a standard postoperative treatment for cerebral glioma. We have observed the onset of symptoms related to brain necrosis, as opposed to recurrent tumor, in surviving patients. This has been manifest as dementia with a computed tomographic pattern of low density in the frontal lobe uninvolved with tumor, but within the field of radiotherapy. Two patients presented with mass lesions also unrelated to recurrent tumor. We question the necessity of full brain irradiation and suggest that radiotherapy techniques be altered to target the tumor and not encompass the entire brain.

APA, Harvard, Vancouver, ISO, and other styles

23

Hasegawa, Toshinori, Douglas Kondziolka, John C. Flickinger, Anand Germanwala, and L. Dade Lunsford. "Brain Metastases Treated with Radiosurgery Alone: An Alternative to Whole Brain Radiotherapy?" Neurosurgery 52, no. 6 (June 1, 2003): 1318–26. http://dx.doi.org/10.1227/01.neu.0000064569.18914.de.

Full text

Abstract:

Abstract OBJECTIVE Whole brain radiotherapy (WBRT) provides benefit for patients with brain metastases but may result in neurological toxicity for patients with extended survival times. Stereotactic radiosurgery in combination with WBRT has become an important approach, but the value of WBRT has been questioned. As an alternative to WBRT, we managed patients with stereotactic radiosurgery alone, evaluated patients' outcomes, and assessed prognostic factors for survival and tumor control. METHODS One hundred seventy-two patients with brain metastases were managed with radiosurgery alone. One hundred twenty-one patients were evaluable with follow-up imaging after radiosurgery. The median patient age was 60.5 years (age range, 16–86 yr). The mean marginal tumor dose and volume were 18.5 Gy (range, 11–22 Gy) and 4.4 ml (range, 0.1–24.9 ml). Eighty percent of patients had solitary tumors. RESULTS The overall median survival time was 8 months. The median survival time in patients with no evidence of primary tumor disease or stable disease was 13 and 11 months. The local tumor control rate was 87%. At 2 years, the rate of local control, remote brain control, and total intracranial control were 75, 41, and 27%, respectively. In multivariate analysis, advanced primary tumor status (P = 0.0003), older age (P = 0.008), lower Karnofsky Performance Scale score (P = 0.01), and malignant melanoma (P = 0.005) were significant for poorer survival. The median survival time was 28 months for patients younger than 60 years of age, with Karnofsky Performance Scale score of at least 90, and whose primary tumor status showed either no evidence of disease or stable disease. Tumor volume (P = 0.02) alone was significant for local tumor control, whereas no factor affected remote or intracranial tumor control. Eleven patients developed complications, six of which were persistent. Nineteen (16.5%) of 116 patients in whom the cause of death was obtained died as a result of causes related to brain metastasis. CONCLUSION Brain metastases were controlled well with radiosurgery alone as initial therapy. We advocate that WBRT should not be part of the initial treatment protocol for selected patients with one or two tumors with good control of their primary cancer, better Karnofsky Performance Scale score, and younger age, all of which are predictors of longer survival.

APA, Harvard, Vancouver, ISO, and other styles

24

Bikfalvi, A., T. Daubon, and C. Billottet. "P11.65 Insights into the mechanisms of primary brain tumor invasion." Neuro-Oncology 21, Supplement_3 (August 2019): iii58—iii59. http://dx.doi.org/10.1093/neuonc/noz126.211.

Full text

Abstract:

Abstract We have made progress in unravelling the mechanisms of tumor cell invasion by focusing the attention on two molecular pathways including chemokines and extracellular matrix molecules. Chemokines are important mediators of cell signaling that operate both on normal cells and tumor cells and in the immune-cell compartment (Billottet et al, 2013). Among the chemokine receptors, CXCR3 mediate diverse biological functions and comes in two major isoforms the A and B isoform. We found that ligand affinities and conformational changes are very different for the A and B form. We have recently elucidated the role and mechanism of CXCR3A in GBM invasion (Boyé et al, 2017b). We demonstrated that agonist stimulation enhances in vitro cell migration and invasion in GBM cells. A major finding was that CXCR3A forms a complex with the trafficking receptor Lipoprotein-related receptor-1 (LRP1). Silencing of LRP1 leads to an increase in the magnitude of ligand-induced conformational change with CXCR3-A focalized at the cell membrane, leading to sustained receptor activity and increase in the migration. This was also clinically validated. Our study defines LRP1 as a new regulator of CXCR3 and indicates that targeting CXCR3-A in GBM may constitute a promising strategy to halt tumor cell invasion. The extracellular matrix (ECM) has morphogenic roles in tumors. Important ECM components are the matricellular proteins, called thrombospondins(THBS1-5) (Adams and Lawler 2011). We recently elucidated the complex role of THSB1 in GBM invasion (Daubon et al.2019). Global expression analysis revealed that THBS1 is up-regulated in GBMs and associated with a poor prognosis. We, furthermore, demonstrated that THBS1 did not activate TGFβ in GBM but that TGFβ1 induced the expression of THBS1 via SMAD3. Furthermore, GBM invasion is compromised when THBS1 is silenced in tumor cells. Thus, our data clearly show that THBS1 is not only involved in the regulation of angiogenesis in GBM, but also impacts the invasive behaviour of glioma cells by interacting with a molecule called CD47 expressed on the surface of GBM cells. RNA-sequencing after microdissection of central and peripheral tumour areas in a human PDX model demonstrated that THBS1 was the gene with the highest connectivity in the peripheral invasive tumour areas. Taken together, these data indicate that THBS1 plays important role in the infiltrative process in GBM. REFERENCES: Adams JC, Lawler J. Cold Spring Harb Perspect Biol. 2011;3:a009712 Billottet C, Quemener C, Bikfalvi A. Biochim Biophys Acta. 2013;1836:287- Boyé K et al. Sci Rep. 2017;7:10703 Boyé K et al. Nat Commun. 2017;8:1571 Daubon T et al, Nature Communications. Nat Commun. 2019 Mar 8;10(1):1146 Murphy-Ullrich JE, Poczatek M. Cytokine Growth Factor Rev. 2000 11:59

APA, Harvard, Vancouver, ISO, and other styles

25

Vranic, Andrej, and Frederic Gilbert. "Prognostic Implication of Preoperative Behavior Changes in Patients with Primary High-Grade Meningiomas." Scientific World Journal 2014 (2014): 1–5. http://dx.doi.org/10.1155/2014/398295.

Full text

Abstract:

High-grade meningiomas are rare extra-axial tumors, frequently causing brain invasion and prominent brain edema. Patients harboring high-grade meningiomas occasionally present with behavior changes. Data about frequency and prognostic importance of preoperative behavior changes in patients with high-grade meningiomas is missing. 86 patients with primary high-grade meningiomas were analyzed. Statistical analysis was performed to determine correlation of preoperative behavior changes with tumor location, preoperative brain edema, tumor cleavability, tumor grade, Ki67 proliferation index, and microscopic brain invasion. Survival analysis was performed. 30 (34.9%) patients presented with preoperative behavior changes. These changes were more frequent with male patients (P=0.066) and patients older than 55 years (P=0.018). They correlated with frontal location (P=0.013), tumor size (P=0.023), microscopic brain invasion (P=0.015), and brain edema (P=0.006). Preoperative behavior changes did not correlate with duration of symptoms, tumor cleavability, tumor malignancy grade, and Ki67 proliferation index. They were not significantly related to overall survival or recurrence-free survival of patients with primary high-grade meningiomas. Preoperative behavior changes are frequent in patients harboring primary high-grade meningiomas. They correlate with tumor size, microscopic brain invasion, and brain edema. Preoperative behavior changes do not predict prognosis in patients with primary high-grade meningiomas.

APA, Harvard, Vancouver, ISO, and other styles

26

Akter, Farhana, Brennan Simon, Nadine Leonie de Boer, Navid Redjal, Hiroaki Wakimoto, and Khalid Shah. "Pre-clinical tumor models of primary brain tumors: Challenges and opportunities." Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875, no. 1 (January 2021): 188458. http://dx.doi.org/10.1016/j.bbcan.2020.188458.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Nejo, Takahide, Abigail Mende, and Hideho Okada. "The current state of immunotherapy for primary and secondary brain tumors: similarities and differences." Japanese Journal of Clinical Oncology 50, no. 11 (September 28, 2020): 1231–45. http://dx.doi.org/10.1093/jjco/hyaa164.

Full text

Abstract:

Abstract Treatment and resolution of primary and metastatic brain tumors have long presented a challenge to oncologists. In response to the dismal survival outcomes associated with conventional therapies, various immunotherapy modalities, such as checkpoint inhibitors, vaccine, cellular immunotherapy and viral immunotherapy have been actively explored over the past couple of decades. Although improved patient survival has been more frequently noted in treatment of brain metastases, little progress has been made in improving patient survival in cases of primary brain tumors, specifically glioblastoma, which is the representative primary brain tumor discussed in this review. Herein, we will first overview the findings of recent clinical studies for treatment of primary and metastatic brain tumors with immunotherapeutic interventions. The clinical efficacy of these immunotherapies will be discussed in the context of their ability or inability to overcome inherent characteristics of the tumor as well as restricted antigen presentation and its immunosuppressive microenvironment. Additionally, this review aims to briefly inform clinicians in the field of neuro-oncology on the relevant aspects of the immune system as it pertains to the central nervous system, with special focus on the differing modes of antigen presentation and tumor microenvironment of primary and metastatic brain tumors and the role these differences may play in the efficacy of immunotherapy in eradicating the tumor.

APA, Harvard, Vancouver, ISO, and other styles

28

Chen, Likun, Lihong Wu, Meichen Li, Huan Chen, Lijia Wu, Pei Hao, and Ji He. "Comparison of immune microenvironment between primary lung tumors and paired brain metastatic tumors." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 2020. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2020.

Full text

Abstract:

2020 Background: Lung cancer is one of the most common causes of brain metastases (BMs) and is always associated with poor prognosis. To evaluate the characteristics of the tumor immune microenvironment in brain metastases of non-small-cell lung cancer (NSCLC), we investigated the immunophenotype of primary NSCLC and paired brain metastases. Methods: Forty-three Chinese patients with NSCLC who had BMs at presentation or during the course of their disease were admitted to the Sun Yat-Sen University Cancer Center (Guangzhou, China) from 2000 to 2019. RNA sequencing (RNA-seq) of eighty-six formalin-fixed, paraffin embedded (FFPE) samples from primary lung tumors and paired brain metastases of 43 patients was conducted to comprehensively analyze the tumor immune microenvironment. Results: Our data revealed that brain metastases compared with primary lung tumors exhibited reduced tumor infiltrating lymphocytes (TILs) (all 28 immune cell subtypes P < 0.05), lower fraction of activated CD8 T cell and effector memory CD8 T cell in total TILs (P = 0.028, P < 0.001, respectively); higher fraction of macrophage and neutrophil in total TILs (P < 0.001, P < 0.01, respectively). Comparing with the primary lung tumors, the scores of some immune related signatures, including MHC non-class signature, IFN gamma signature and T-cell-inflamed gene-expression profile (GEP) signature, were significantly lower in brain metastases (P = 0.004, P = 0.009, P = 0.004, respectively), while the score of MHC class-II signature was higher in brain metastases (P = 0.045). We found the distributions of tumor microenvironment immune types (TMIT) in brain metastases and primary lung tumors were different. Brain metastases contained significantly lower proportion of TMIT I (high PD-L1/ high CD8A) (23%) than primary lung tumors (47%) (P < 0.05). Besides, we found three immune inhibitory checkpoint molecules, namely C10orf54 (VISTA), CTLA4 and CD274 (PD-L1) were downregulated in brain metastases than in primary lung tumors (P < 0.001, P < 0.001, P = 0.034, respectively). Moreover, there was poor correlation of PD-L1 expression between paired brain metastases and primary lung tumors (R = 0.28, P = 0.068). Unsupervised hierarchic cluster analysis revealed the primary lung tumors had two distinct patterns of immune gene signatures, namely Cluster A and Cluster B, and the tumors in Cluster B were immune rich, but associated with poor prognosis (log-rank P = 0.021). Conclusions: Our work illustrates the immune landscape of brain metastases from NSCLC, and suggests that the tumor immune microenvironment in brain metastases compared with primary lung tumors is further immunosuppressed, that may help guide immunotherapeutic strategies for NSCLC brain metastases.

APA, Harvard, Vancouver, ISO, and other styles

29

Mrdak, Milan, Miljan Mihajlovic, Igor Nikolic, Nikola Repac, Vladimir Jovanovic, Vuk Scepanovic, Aleksandar Janicijevic, Ivan Bogdanovic, Branislav Nestorovic, and Goran Tasic. "The results of treatment of primary brain tumors in children." Acta chirurgica Iugoslavica 59, no. 1 (2012): 45–48. http://dx.doi.org/10.2298/aci1201045m.

Full text

Abstract:

During the period of 2009-2011 in UCH in Belgrade, we treated 22 patients with brain tumors. Treatment included the diagnosis and therapy that included surgery and postoperative neuroradiological follow-up of all patients regardless of whether radiotherapy was conducted with or without chemotherapy. The most frequent were low grade astrocytomas and medulloblastomas. Patients with supratentorial localization of tumor had significantly smaller neurological sequelae compared with patients with infratentorial as well as patients diagnosed with low grade astrocytomas of any localization. From 10 patients with supratentorial localization,7 of them had no neurological deficit, while from 11 patients with infratentorial localization, 3 of them were without deficit. Patients with histological diagnosis of low grade astrocytoma of any localization had less neurological deficits compared with other tumors. From 7 low grade astrocytoma in 5 of them there was no neurological deficit, while only in one patient residual tumor was verified. In 7 patients the rest of the tumor was diagnosed, while in 14 patients no residual tumors was diagnosed during follow-up based on the MRI diagnosis. Surgery, postoperative radiotherapy and chemotherapy in some cases represent an effective therapeutic approach in the treatment of brain tumors in children.

APA, Harvard, Vancouver, ISO, and other styles

30

Ogiya, Rin, Naoki Niikura, Nobue Kumaki, Hiroyuki Yasojima, Tsutomu Iwasa, Chizuko Kanbayashi, Risa Oshitanai, et al. "Immune microenvironment in brain metastases of breast cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 1081. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.1081.

Full text

Abstract:

1081 Background: In patients with brain metastasis (BM) of melanoma or lung cancer, significant activity of immune checkpoint inhibitors has been reported. However, details of the immune microenvironment in BM has not been unveiled. In this study, we used immunohistochemistry (IHC) to compare primary breast tumors and BM tumor samples with respect to tumor infiltrating lymphocytes (TILs) and tumor characteristics related to the immune system. Methods: We retrospectively identified 107 patients with breast cancer, diagnosed with BM, who had undergone surgery between 2001 and 2012 at 8 institutions. We collected 191 samples which included both BM samples alone and pair-matched samples (primary and BM). Hematoxylin and eosin (H&E) stained slides were evaluated for stromal TILs in 10% increments (0–1%, > 1– < 10%, 10%–100%). IHC was performed using the following primary antibodies: CD4, CD8, Foxp3, PD-L1, PD-L2 and HLA class I. The cells positive for each antibody signal were counted automatically using ImageJ (NIH). The expression of PD-L1, PD-L2, and HLA on the tumor cells was scored as 0 (negative), 1 (weak or focal), or 2 (strong). Results: The median category of TILs of BM tumors was > 1– < 10% (range: 1–30%). Forty-six pair-matched samples were analyzed and the percentage of TILs in the primary breast tumor was significantly higher than that in BM samples (paired t-test, P < 0.01). The number of CD4/CD8/Foxp3 positive cells in primary breast tumor was also significantly higher than in BM samples (paired t-test, P < 0.05 for all categories). The negative/positive conversion occurred with the expression of HLA/PD-L2 on tumor cells (paired t-test, P = 0.03/0.06, respectively). No significant difference was observed in the overall survival (OS) of patients, from initial BM, based on high or low TILs (log-rank test, P = 0.131). However, triple negative breast cancer patients with low TILs had significantly shorter OS compared with patients with high TILs (log-rank test, P = 0.04). Conclusions: We demonstrated that TILs in BM tumors was significantly lower as compared to primary breast tumors. The expression of immune related molecules on tumor cells was converted in BM tumors.

APA, Harvard, Vancouver, ISO, and other styles

31

Demyashkin, G. A., E. A. Shalamova, P. V. Nikitin, and S. N. Bogomolov. "Immunophenotypic characteristics of brain metastases." Neurology, Neuropsychiatry, Psychosomatics 10, no. 4 (December 15, 2018): 59–64. http://dx.doi.org/10.14412/2074-2711-2018-4-59-64.

Full text

Abstract:

Up to 15% of patients with secondary brain tumors of unknown primary are admitted to a neurosurgery department. Identification of a primary tumor site on the basis of surgical material immunophenotyping in routine clinical practice has a significant potential; however, this requires systematization.Objective: to detect the primary focus of brain carcinoma. Patients and methods.Surgical specimens from 7 patients with brain tumor of unknown primary were investigated using light optical microscopy and an immunohistochemical (IHC) panel including EMA, CK AE1/3, CK7, CK5/6, GFAP, S-100, Vimentin, p63, TTF-1, Uroplakin III (UPIII), CDX2, and Her2/neu.Results and discussion. A study using the IHC panel made it possible to obtain the following tumor phenotypes in the patients: CK5/6+, p63+, CK7+, UPIII+ (urothelial cancer) (n=3); CK5/6-, CK7+, TTF-1+, CDX2- (lung adenocarcinoma) (n=2); CK5/6+, p63+, CK7-, UPIII, TTF-1- (squamous cell carcinoma) (n=1), and CK5/6-, CK7+, TTF-1-, CDX2-, Her2/neu+ (breast cancer) (n=1). Evidence of the primary focus of the tumors was subsequently confirmed by instrumental techniques in all cases when cancer of the breast, lung and urinary system was directly sought. The findings were used to elaborate an algorithm for the differential diagnostic immunophenotyping of brain metastases.Conclusion. The primary focus of brain carcinoma was detected in all cases on the proposed IHC panel. The systematized algorithm for differential diagnostic immunophenotyping can be used in clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

32

Rubino, Franco, Daniel G. Eichberg, Ashish H. Shah, Evan M. Luther, Victor M. Lu, Ali G. Saad, David Kahn, Ricardo J. Komotar, and Michael E. Ivan. "When “Peripheral” Becomes “Central”: Primary and Secondary Malignant Intracerebral Nerve Sheath Tumor: A Case Report and a Systematic Review." Neurosurgery 88, no. 6 (February 27, 2021): 1074–87. http://dx.doi.org/10.1093/neuros/nyab043.

Full text

Abstract:

Abstract BACKGROUND The intracerebral occurrence of malignant peripheral nerve sheath tumors (MPNSTs) is exceedingly rare, and despite aggressive treatments, local recurrence and poor prognosis are very frequent. Like other brain tumors, these tumors could be primary or secondary, making the term “peripheral” an imprecise term for a primary brain tumor. OBJECTIVE To analyze the reported cases of primary and secondary cerebral MPSNTs in terms of diagnosis, treatment, and overall survival. Additionally, we present a case of malignant intracerebral nerve sheath tumor (MINST) treated with radical surgery and radiotherapy. METHODS Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, one database (PubMed) and crossed references were queried for MPNST with brain metastasis and primary MINSTs from 1971 to 2020. Data regarding demographic features, primary tumor site, risk factors, brain location of the lesion, treatment applied, and overall survival were extracted. RESULTS A total of 55 patients were selected (including the reported case): 29 patients were secondary brain MPNST and 26 patients were primary MINST. The mean age was 41.8 ± 22 and 31.2 ± 23 yr, respectively. All brain metastases of MPNST (100%) had a primary tumor elsewhere in the body at the time of diagnosis. The overall survival was significantly shorter in patients with a secondary brain MPNST compared to MINST (P = .002). CONCLUSION We present a comprehensive analysis of every reported primary and secondary intracerebral MPNST. The prognosis in terms of survival is worst in the last one despite aggressive treatment. The lack of a primary MPNST in screening tests is sufficient to confirm a MINST at time of diagnosis.

APA, Harvard, Vancouver, ISO, and other styles

33

Shao, Yu Yun, Min-Shu Hsieh, Chung-Yi Huang, Li-Chun Lu, Chih-Hung Hsu, and Ann-Lii Cheng. "Unique histopathologic features of brain metastases from hepatocellular carcinoma." Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 169. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.169.

Full text

Abstract:

169 Background: In the era of anti-angiogenic therapy as treatment for advanced hepatocellular carcinoma (HCC), the incidence and importance of brain metastases are increasing. We aimed to study their histopathologic features. Methods: We searched for all patients who were diagnosed to have HCC with brain metastasis from 1999 to 2010 at National Taiwan University Hospital, Taipei, Taiwan. Patients who had HCC with lung metastasis were also included for comparison. Patients with available tissues of both primary and metastatic tumors were enrolled in this study. Tumor slides from paired primary and metastatic HCCs were stained by H and E, and immunohistochemically stained for CK7, p53, Ki67, vimentin, Hes1, and c-Met. The expressions of CK7, p53, and vimentin were graded according to percentages of positive staining, but those of Hes1 and c-Met were recorded as an H score, which was defined as intensity (0, 1, 2, or 3) × percentages of positive staining. Results: A total of 14 patients had available tumor tissues of both primary and metastatic brain tumors. Another 21 patients had tumor tissues of both primary and metastatic lung tumors. The metastatic brain tumors, comparing to the metastatic lung tumors, had significantly more bizarre dilated vessels (86% vs. 14%, p < 0.001), hyaline globules (50% vs. 5%, p = 0.003), higher Hes1 H scores (mean, 245 vs. 131, p = 0.001), and lower c-Met H scores (mean, 15.4 vs. 38.1, p = 0.046). Tumor necrosis also tended to be more common among metastatic brain tumors (93% vs. 62%, p = 0.056). On the contrary, the above differences were not identified between the primary tumors which later developed brain metastasis and those which later developed lung metastasis. When disease progressed from primary liver to brain metastasis, mitosis counts (p = 0.034) and bizarre dilated vessels (p = 0.020) significantly increased, and necrosis (p = 0.059) tended to be more common. Conclusions: Metastatic brain tumors from HCC had unique histopathologic features compared to primary liver tumors or lung metastases. The increased Hes1 expression and decreased c-Met expression in HCC brain metastasis should be further explored. (This study was supported by the grant of NSC101-2314-B-002 -141, 100CAP1020-2 & NTUH.101-N1965.)

APA, Harvard, Vancouver, ISO, and other styles

34

Miele, William R., Rolf Pfannl, and James T. Kryzanski. "Primary holocord ganglioneuroblastoma." Journal of Neurosurgery: Spine 15, no. 4 (October 2011): 457–63. http://dx.doi.org/10.3171/2011.5.spine10563.

Full text

Abstract:

The authors present a case of extensive primary intramedullary spinal CNS ganglioneuroblastoma (GNB) in a 23-year-old man. Central nervous system GNB is a poorly differentiated neuroepithelial tumor composed of neuroblasts and differentiated ganglion cells, and these lesions are extremely uncommon. Most previously reported primary intraaxial neuroblastic tumors were described in the brain. There has been only one other report of primary spinal cord CNS GNB published to date; the clinical course and prognosis for primary spinal cord tumors of this type are unknown. Similar tumor types demonstrate poor prognoses. This 23-year-old man presented after 9 months of progressive myelopathy. Admission MR imaging showed an intraaxial enhancing mass extending from C-3 to the conus medullaris, with a holocord appearance in several areas. Due to the tumor size, operative intervention was initially limited to biopsy sampling. Chemotherapy resulted in histological maturation, but initial tumor regression was temporary. The patient suffered progressive quadriparesis, and neuroimaging demonstrated slow enlargement of the tumor and an associated syrinx. Nineteen months after diagnosis, the tumor was excised to gross-total resection in a 2-stage operation. One year following resection, the patient had no radiographic recurrence and was functional in a wheelchair with minimal paresis in the upper extremities. This case represents the most extensive example of primary spinal intramedullary CNS GNB reported to date. Holocord tumors present a significant challenge to the neurosurgeon, and resection bears substantial risk of morbidity. In spinal cord CNS GNB, chemotherapy followed by complete resection may be the most effective means of tumor control.

APA, Harvard, Vancouver, ISO, and other styles

35

Ghanta, RajeshK, Kalyan Koti, Monalisa Hui, MeghaS Uppin, ShantveerG Uppin, and KanchanK Mukherjee. "Primary intracranial Parachordoma: An unusual tumor in brain." Surgical Neurology International 5, no. 15 (2014): 506. http://dx.doi.org/10.4103/2152-7806.145664.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Leung, Denise, Xiaosi Han, Tom Mikkelsen, and L. Burt Nabors. "Role of MRI in Primary Brain Tumor Evaluation." Journal of the National Comprehensive Cancer Network 12, no. 11 (October 31, 2014): 1561–68. http://dx.doi.org/10.6004/jnccn.2014.0156.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Rushing, Elisabeth J., John Paul Bouffard, Chris J. Neal, Kelly Koeller, Jonathan Martin, Metin Ozdemirli, Hernando Mena, and James M. Ecklund. "Erdheim—Chester disease mimicking a primary brain tumor." Journal of Neurosurgery 100, no. 6 (June 2004): 1115–18. http://dx.doi.org/10.3171/jns.2004.100.6.1115.

Full text

Abstract:

✓ Erdheim—Chester disease (ECD) is a rare systemic histiocytic disease. The authors present a case report detailing the presentation and treatment of a 26-year-old man diagnosed with seizures and a well-circumscribed temporoparietal mass that had been demonstrated on imaging studies. Both preoperative and intraoperative diagnoses were consistent with a low-grade astrocytic neoplasm. Subsequent pathological examination indicated a histiocytic proliferation positive for CD68 and factor VIII, and negative for CD1a and S100, with Touton giant cells characteristic of ECD. This case represents the first isolated occurrence of intracranial ECD and its potential to mimic glial neoplasms.

APA, Harvard, Vancouver, ISO, and other styles

38

Hohwieler, M. L., T. C. Lo, M. L. Silverman, and S. R. Freidberg. "Brain necrosis after radiotherapy for primary intracerebral tumor." Neurosurgery 18, no. 1 (January 1986): 67???74. http://dx.doi.org/10.1097/00006123-198601000-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Sherwood, P. R., M. Stommel, D. L. Murman, C. W. Given, and B. A. Given. "Primary malignant brain tumor incidence and Medicaid enrollment." Neurology 62, no. 10 (May 24, 2004): 1788–93. http://dx.doi.org/10.1212/01.wnl.0000125195.26224.7c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Hoshide, Reid, and Rahul Jandial. "Predicting Brain Metastasis Radiosensitivity From Primary Tumor Biology." Neurosurgery 79, no. 2 (August 2016): N23—N24. http://dx.doi.org/10.1227/01.neu.0000489892.55106.ab.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Lin, Bon-Jour, and Hsin-I. Ma. "Primary Central Nervous System Vasculitis Mimicking Brain Tumor." Neurosurgery Quarterly 25, no. 4 (November 2015): 499–501. http://dx.doi.org/10.1097/wnq.0000000000000093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Nelson, Sarah, and Lynne P. Taylor. "Headaches in Brain Tumor Patients: Primary or Secondary?" Headache: The Journal of Head and Face Pain 54, no. 4 (April 2014): 776–85. http://dx.doi.org/10.1111/head.12326.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Allalunis-Turner, M. Joan, Geraldine M. Barron, Rufus S. Day, Dorcas S. Fulton, and Raul C. Urtasun. "Radiosensitivity testing of human primary brain tumor specimens." International Journal of Radiation Oncology*Biology*Physics 23, no. 2 (January 1992): 339–43. http://dx.doi.org/10.1016/0360-3016(92)90751-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Durand, Thomas, Giulia Berzero, Flavie Bompaire, Sabine Hoffmann, Isabelle Léger, Virginie Jego, Marie Baruteau, et al. "Episodic Memory Impairments in Primary Brain Tumor Patients." Archives of Clinical Neuropsychology 33, no. 8 (January 4, 2018): 949–55. http://dx.doi.org/10.1093/arclin/acx138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Dwary, Ashish Dutta, Ankita Gupta, Gary Von Burton, and Prakash Peddi. "Primary brain tumor and risk of venous thromboembolism." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e13518-e13518. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13518.

Full text

Abstract:

e13518 Background: Venous thromboembolism (VTE) is frequently associated with primary brain tumors (PBT). Brain tumors have been associated with higher rates of VTE in multiple studies. Studies comparing VTE incidence in meningioma (MEN), astrocytoma (AA), oligodendroglioma (OG) and glioblastoma multiforme (GBM) are lacking. The aim of this retrospective study is to report the VTE outcomes in all of the above brain tumors. Methods: Retrospective data from 476 patients with PBTs diagnosed between 1995-2015 at Louisiana State University Health Sciences Center-Shreveport was analyzed. The incidence of VTE (deep vein thrombosis or pulmonary embolism) was studied in these patients. Results: Out of 476 patients, 298 were females and 179 were male. One hundred and twenty seven (127) patients had GBM, 52 had AA, 33 had OG and 264 had MEN. Only two patients out of 264 with MEN had VTE (one patient had central line catheter associated DVT). VTE incidence did not correlate with the type of primary treatment i.e surgery verses radiation verses observation in this patient group. The incidence of VTE was 7.8 % in GBM patients. The risk of VTE in AA and OG patients were 7.7% and 9.0 % respectively. The VTE event in the OG, AA and GBM occurred during all phases of treatment including inpatient hospitalization for surgical resection, during concurrent chemo-radiation and in maintenance phase. Biopsy versus partial resection versus complete resection of GBM didn’t correlate with VTE occurrence. Conclusions: VTE is prevalent among adult patients with both low and high grade glial tumors. The thrombotic events occur during all phases of therapy indicating hypercoagulable state for many patients. Life-long anticoagulation may be necessary in these patients with thrombotic events. Thrombotic events in patients with MEN, however, are rare ( < 1%). MEN do not appear to be a hypercoagulable and life-long anticoagulation is probably unnecessary in those with VTE.

APA, Harvard, Vancouver, ISO, and other styles

46

Kowal-Vern, Areta, Imad Almanaseer, and Archie Bleyer. "Intracranial Lymphoblastic Sarcoma Mimicking a Primary Brain Tumor." Pediatric Neurosurgery 15, no. 3 (1989): 136–38. http://dx.doi.org/10.1159/000120459.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Greenberg, H., and P. R. Sherwood. "Primary malignant brain tumor incidence and Medicaid enrollment." Neurology 63, no. 11 (December 13, 2004): 2197. http://dx.doi.org/10.1212/wnl.63.11.2197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Alleemudder, Adam, and Rajiv Pillai. "Bilateral Renal Involvement From a Primary Brain Tumor." World Journal of Nephrology and Urology 5, no. 1 (2016): 23–25. http://dx.doi.org/10.14740/wjnu252w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Katakowski, Mark, and Michael Chopp. "Exosomes as Tools to Suppress Primary Brain Tumor." Cellular and Molecular Neurobiology 36, no. 3 (March 17, 2016): 343–52. http://dx.doi.org/10.1007/s10571-015-0280-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Nanassis, Kimon, C. Alexiadou-Rudolf, Philippos Tsitsopoulos, Valentini Tzioufa, Georgios Petsas, and Konstantinos Grigoriou. "Solid cerebral echinococcosis mimicking a primary brain tumor." Neurosurgical Review 22, no. 1 (April 5, 1999): 58–61. http://dx.doi.org/10.1007/s101430050011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Primary brain tumor'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles